A circRNA signature predicts postoperative recurrence in stage II/III colon cancer

  • Ju H
  • Zhao Q
  • Wang F
  • et al.
115Citations
Citations of this article
73Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

© 2019 The Authors. Published under the terms of the CC BY 4.0 license Accurate risk stratification for patients with stage II/III colon cancer is pivotal for postoperative treatment decisions. Here, we aimed to identify and validate a circRNA-based signature that could improve postoperative prognostic stratification for these patients. In current retrospective analysis, we included 667 patients with R0 resected stage II/III colon cancer. Using RNA-seq analysis of 20 paired frozen tissues collected postoperation, we profiled differential circRNA expression between patients with and without recurrence, followed by quantitative validation. With clinical information, we generated a four-circRNA-based cirScore to classify patients into high-risk and low-risk groups in the training cohort. The patients with high cirScores in the training cohort had a shorter disease-free survival (DFS) and overall survival (OS) than patients with low cirScores. The prognostic capacity of the classifier was validated in the internal and external cohorts. Loss-of-function assays indicated that the selected circRNAs played functional roles in colon cancer progression. Overall, our four-circRNA-based classifier is a reliable prognostic tool for postoperative disease recurrence in patients with stage II/III colon cancer.

Cite

CITATION STYLE

APA

Ju, H., Zhao, Q., Wang, F., Lan, P., Wang, Z., Zuo, Z., … Xu, R. (2019). A circRNA signature predicts postoperative recurrence in stage II/III colon cancer. EMBO Molecular Medicine, 11(10). https://doi.org/10.15252/emmm.201810168

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free